10 completed, 10 recruiting, 8 unknown, 6 not yet recruiting. 19 Phase 2, 8 Not applicable, 8 Phase 1, 4 Phase 3, 2 Early Phase 1.
Follow this condition Literature Review of Oral Cavity Squamous Cell Carcinoma trials Research Report on Oral Cavity Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Mayo Clinic | 30 | 2026-09-07 | 2026-08-25 |
| H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) XL092, Pembrolizumab - Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 26 | 2026-09-01 | 2026-08-31 |
| Study Comparing Limited and Extensive Neck Surgery in Oral Cancer Patients With Neck Spread Selective Neck Dissection (Levels I-IV), Modified Neck Dissection (Levels I-V) - Oral Cavity Squamous Cell Carcinoma | Not applicable | Recruiting | Kolhapur Cancer Centre - Cancer Centers of America | 80 | 2026-08-01 | 2026-08-04 |
| APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma APG-157, Surgery, Radiation/Chemotherapy - Head and Neck Cancer, Head and Neck (HNSCC) | Phase 3 | Not yet recruiting | Aveta Biomics, Inc. | 826 | 2026-07-01 | 2026-07-01 |
| Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers Acupuncture - Xerostomia, Head Cancer | Not applicable | Not yet recruiting | National University Hospital, Singapore | 50 | 2026-06-01 | 2026-06-29 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-16 |
| Artificial Intelligence for the Diagnosis of Oral Lesions Oral Potentially Malignant Disorders, Oral Cavity Squamous Cell Carcinoma | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 5000 | 2026-04-01 | 2026-04-14 | |
| Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma Chemotherapy, Lattice Radiotherapy (LRT) - Oral Cavity Squamous Cell Carcinoma | Phase 1 | Not yet recruiting | NYU Langone Health | 30 | 2026-04-01 | 2026-01-29 |
| Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer Compartmentalized Postoperative Radiotherapy - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Olgun Elicin | 50 | 2026-01-15 | 2026-08-27 |
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial Biospecimen Collection, Carboplatin, Cisplatin - Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8 | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 50 | 2025-07-17 | 2026-07-31 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel Squamous Cell Carcinoma of Oropharynx, Squamous Cell Carcinoma of the Hypopharynx | Recruiting | University of Erlangen-Nürnberg Medical School | 250 | 2025-05-01 | 2026-07-31 | |
| A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery Near Infrared Imaging, Therapeutic Conventional Surgery, Tozuleristide - Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8 | Phase 1 / Phase 2 | Terminated | University of Washington | 8 | 2024-04-17 | 2026-09-16 |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer Biospecimen Collection, Carboplatin, Chest Radiography - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Withdrawn | ECOG-ACRIN Cancer Research Group | 2024-04-12 | 2024-07-25 | |
| Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) NisinZ® P, Surgery (non-interventional, standard of care) - Oral Cavity Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 40 | 2024-02-02 | 2026-04-13 |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Zimberelimab, Etrumadenant, Cisplatin - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Withdrawn | Jennifer Choe | 2023-12-31 | 2023-11-30 | |
| Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). Tiragolumab, Atezolizumab, Standard of Care - Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 29 | 2023-06-02 | 2026-06-02 |
| A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma Sintilimab, Radiotherapy - Oral Cavity Squamous Cell Carcinoma | Phase 2 | Unknown | Xin-Hua Xu | 70 | 2023-01-18 | 2023-03-01 |
| Articulatory Adaptation Following Oral Cancer Treatment Electromagnetic Articulography - Oral Cavity Squamous Cell Carcinoma, Speech Disorders | Unknown | University Medical Center Groningen | 50 | 2022-11-10 | 2023-05-30 |
Showing 20 of 45. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (45) · Mouth Neoplasms (16) · Head and Neck Neoplasms (11) · Laryngeal Neoplasms (7) · Carcinoma, Squamous Cell (6) · Carcinoma (5) · Hypopharyngeal Neoplasms (5) · Nasopharyngeal Carcinoma (5) · Oropharyngeal Neoplasms (4) · Disease (1) · Laryngeal Diseases (1) · Lymphoid Interstitial Pneumonia (1) · Neoplastic Cells, Circulating (1) · Pharyngeal Neoplasms (1) · Speech Disorders (1)
Neoplasms (45) · Neoplasms by Histologic Type (45) · Neoplasms by Site (45) · Neoplasms, Glandular and Epithelial (45) · Carcinoma (40) · Carcinoma, Squamous Cell (39) · Head and Neck Neoplasms (34) · Stomatognathic Diseases (18) · Mouth Diseases (17) · Otorhinolaryngologic Diseases (10) · Otorhinolaryngologic Neoplasms (9) · Pharyngeal Diseases (8) · Respiratory Tract Diseases (8) · Laryngeal Diseases (7) · Pharyngeal Neoplasms (7)
Cisplatin (8) · Magnetic Resonance Spectroscopy (6) · Carboplatin (5) · Specimen Handling (5) · durvalumab (4) · pembrolizumab (4) · 1,2-diaminocyclohexaneplatinum II citrate (3) · Platinum (3) · Radiation (3) · Radiotherapy (3) · Radiotherapy, Intensity-Modulated (3) · Sentinel Lymph Node Biopsy (3) · Standard of Care (3) · Surgical Procedures, Operative (3) · X-Rays (3)
NRG Oncology (2) · National Cancer Institute (NCI) (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Wake Forest University Health Sciences (2) · Amsterdam UMC, location VUmc (1) · Assistance Publique - Hôpitaux de Paris (1) · Aveta Biomics, Inc. (1) · Chang Gung Memorial Hospital (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Insel Gruppe AG, University Hospital Bern (1) · Institut de cancérologie Strasbourg Europe (1) · Jennifer Choe (1)
United States (18) · China (4) · Canada (3) · Belgium (2) · France (2) · India (2) · Netherlands (2) · Switzerland (2) · Australia (1) · Germany (1) · Italy (1) · Singapore (1) · Taiwan (1) · United Kingdom (1)
Adam Luginbuhl, MD (1) · Ben Panizza, Assoc Prof (1) · C. R. Leemans, Phd, MD (1) · C. W. Menke, Phd, MD (1) · Christine Chung, M.D. (1) · Chun-Ta Liao, MD (1) · Colin Hill, MD (1) · Daniel K. Ebner, MD, MPH (1) · Darko Macan, PhD, DDS (1) · David M Brizel (1) · David Pass, Mr (1) · Douglas Chepeha, MD (1) · Emily Marchiano (1) · Guopei Zhu (1)
PMID 23225810, PMID 23996343, PMID 26500065, PMID 33605440, PMID 36125263, PMID 36405475, PMID 38820888, PMID 39075531, PMID 39145961, PMID 39551064
P30CA012197 (2), U10CA180868 (2), 2015 (1), 2017 (1), 2018 (1), K24DC022077 (1), P30CA138292 (1), R01CA269950 (1), U10CA180820 (1), UG1CA189867 (1), UM1CA186691 (1)